| CASE REPORT |
|
| Year : 2018 | Volume
: 28
| Issue : 1 | Page : 73-75 |
Eculizumab dosing in infants
M Kobrzynski1, B Wile1, SS Huang2, G Filler3
1 Department of Pediatrics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
2 Department of Medicine, Division of Nephrology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
3 Department of Pediatrics; Departments of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University; Department of Children's Health and Therapeutics, Children's Health Research Institute, London, ON, Canada
Correspondence Address:
Dr. G Filler
Department of Pediatrics, Children's Hospital - London Health Sciences Centre, University of Western Ontario, 800 Commissioner's Road East, Rm B1-138A, London, ON N6A 5W9
Canada
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijn.IJN_310_16
Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome (aHUS). Dosing recommendations stem from two trials: one retrospective trial (19 children and 5 infants) and one prospective trial (22 patients and 5 infants). This case report highlights the need for more precise dosing recommendations in children, particularly in infants, and for smaller vials of the medication to facilitate more precise dosing. Such changes would ensure that adverse events are minimized and that the children with aHUS who are treated with eculizumab experience an optimal clinical response.
[FULL TEXT] [PDF]*
|
|
Editorial Board
